BACKGROUND: Despite significant advances in the screening, detection, and treatment of preinvasive cervical lesions, invasive cervical cancer is the fifth most common cancer in European women. There are large disparities in Europe and worldwide in the incidence, management, and mortality of cervical cancer. OBJECTIVE: The European Society of Gynecological Oncology (ESGO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Society of Pathology (ESP) jointly develop clinically relevant and evidence-based guidelines in order to improve the quality of care for women with cervical cancer across Europe and worldwide. METHODS: The ESGO/ESTRO/ESP nominated an international multidisciplinary development group consisting of practicing clinicians and researchers who have demonstrated leadership and expertise in the care and research of cervical cancer (23 experts across Europe). To ensure that the guidelines are evidence based, the current literature identified from a systematic search was reviewed and critically appraised. In the absence of any clear scientific evidence, judgment was based on the professional experience and consensus of the development group. The guidelines are thus based on the best available evidence and expert agreement. Prior to publication, the guidelines were reviewed by 159 international reviewers, selected through ESGO/ESTRO/ESP and including patient representatives. RESULTS: The guidelines cover comprehensively staging, management, and follow-up for patients with cervical cancer. Management includes fertility sparing treatment; stage T1a, T1b1/T2a1, clinically occult cervical cancer diagnosed after simple hysterectomy; early and locally advanced cervical cancer; primary distant metastatic disease; cervical cancer in pregnancy; and recurrent disease. Principles of radiotherapy and pathological evaluation are defined.

Athens University Athens Greece

Department of Oncology Aarhus University Aarhus Denmark

Department of Pathology Belfast Health and Social Care Trust Belfast UK

Department of Radiation Oncology Leiden University Leiden The Netherlands

Department of Radiation Oncology Tata Memorial Hospital Mumbai India

Department of Radiotherapy Institut Gustave Roussy Villejuif France

Department of Radiotherapy Medical University of Vienna Vienna Austria

Dresden University TU Dresden Dresden Germany

Fondazione IRCCS Istituto Nazionale Tumori Milan Italy

General Hospital Graz Sued West Graz Austria

Gynecologic Oncology Center Department of Obstetrics and Gynecology 1st Faculty of Medicine Charles University and General University Hospital Kateřinská 32 121 08 Prague Czech Republic

Institut Bergonié Bordeaux France

Istituto Nazionale per lo Studio e la Cura dei Tumori Fondazione G Pascale IRCCS Naples Italy

Lausanne University Lausanne Switzerland

Linkoping University Linkoping Sweden

Medical Faculty Department of Gynecology Asklepios Hambourg Altona and University of Cologne Hamburg Germany

Medical University of Graz Graz Austria

Queen Elizabeth Hospital Gateshead UK

University College Hospital London London UK

University Hospital Careggi Florence Italy

University Hospital of Bellvitge Barcelona Spain

University of Milan Bicocca Monza Italy

Virchows Arch. 2018 Jun;472(6):937-938. doi: 10.1007/s00428-018-2380-7. PubMed

Citace poskytuje Crossref.org

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023

ESGO/ESTRO/ESP Guidelines for the management of patients with cervical cancer - Update 2023

Post-recurrence survival in patients with cervical cancer

Micrometastases in Sentinel Lymph Nodes Represent a Significant Negative Prognostic Factor in Early-Stage Cervical Cancer: A Single-Institutional Retrospective Cohort Study